Marija Kalaba

发表

Personalizing health care: feasibility and future implications

Jan Jones, Steven Simoens, Fredrik Nilsson, 2013, BMC Medicine.

Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation

A. Haycox, S. Simoens, B. Godman, 2017, Front. Pharmacol..

Pro-Arrhythmic Potential of Oral Antihistamines (H1): Combining Adverse Event Reports with Drug Utilization Data across Europe

M. Sturkenboom, B. Wettermark, U. Moretti, 2015, PloS one.

Correspondencesharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers

A. Haycox, L. Gustafsson, S. Garattini, 2010 .

Initiatives to increase the prescribing of low cost generics: the case of Scotland in the international context

Schiffers, B. Khan, B. Godman, 2017 .

Torsadogenic Risk of Antipsychotics: Combining Adverse Event Reports with Drug Utilization Data across Europe

M. Sturkenboom, B. Wettermark, C. Barbui, 2013, PloS one.

Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs

T. Cars, R. Malmström, L. Gustafsson, 2014, Front. Pharmacol..

Generic pregabalin: current situation and implications for health authorities, generics and biosimilars manufacturers in the future

R. Malmström, A. Vitry, B. Godman, 2015 .

Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications

B. Wettermark, L. Gustafsson, W. Shrank, 2010, Expert review of pharmacoeconomics & outcomes research.

Policies to Enhance Prescribing Efficiency in Europe: Findings and Future Implications

B. Wettermark, R. Malmström, L. Gustafsson, 2010, Front. Pharmacol..

Policies for biosimilar uptake in Europe: An overview

Steven Simoens, Isabelle Huys, Brian Godman, 2017, PloS one.

Experience with developing antibiotic stewardship programs in Serbia: potential model for other Balkan countries?

S. Janković, B. Godman, M. Prostran, 2018, Journal of comparative effectiveness research.

Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe?

B. Wettermark, L. Gustafsson, W. Shrank, 2010, Pharmaceuticals.

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers

Brian Godman, Silvio Garattini, Alan Haycox, 2010, BMC health services research.

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

Andy Gray, Brian Godman, Ilse Truter, 2015, Expert review of clinical pharmacology.

Initiatives among Authorities to Improve the Quality and Efficiency of Prescribing and the Implications

Brian Godman, Ilse Truter, Andrew Martin, 2016 .

Clinical implications of prenatal diagnosis of aorto-left ventricular tunnel on postnatal treatment and final outcome.

A. Vujic, Z. Mikovic, J. Kosutić, 2017, The Turkish journal of pediatrics.

Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs

A. Haycox, S. Simoens, R. Malmström, 2013, Front. Pharmacol..

Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications

Brian Godman, Samantha Alvarez-Madrazo, Stephen Campbell, 2014, Front. Pharmacol..

Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation

A. Haycox, S. Simoens, B. Godman, 2017, Front. Pharmacol..

Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history?

M. Bennie, B. Godman, Marija Kalaba, 2012, Journal of comparative effectiveness research.

Policies for biosimilar uptake in Europe: An overview

S. Simoens, I. Huys, S. Spillane, 2018 .